journal article·2018-07-05

Self-Regulated Carboxyphenylboronic Acid-Modified Mesoporous Silica Nanoparticles with “Touch Switch” Releasing Property for Insulin Delivery

Lin Hou, Yazhen Zheng, Yongchao Wang, Yurong Hu, Jinjin Shi, Qi Liu, Huijuan Zhang, Zhenzhong Zhang

ACS Applied Materials & Interfaces· Volume 10· Issue 26
Publisher page

Abstract

Glucose-responsive insulin delivery systems, which can maintain a stable level of blood glucose, have been proposed as a promising method to treat diabetes. Such systems can reduce potential toxicity and enhance patient compliance compared to traditional therapies. Accordingly, we designed a mesoporous silica nanoparticle (MSN)-based glucose-sensitive and self-regulated drug release system to achieve the goal of long circulation and "touch switch" in vivo. In this system, carboxyphenylboronic acid (CPBA) was first modified on the surface of MSN using amidation reaction. Insulin (INS) was then loaded in the channels of MSN (CPBA-MSN/INS) through physical adsorption, and sodium alginate (SA) was introduced onto the surface of the CPBA-MSN/INS nanoparticles as the gatekeeper via amidation reaction (SA/CPBA-MSN/INS). We found the drug loading capacity of INS was 261 mg/g. In the normal range of blood glucose, INS was scarcely released due to the reversible covalent interaction between 1,2-diols of SA and CPBA. Within the high concentration of glucose, the boronate esters could be dissociated, which results in the mesoporous channels opening and the release of INS. In vivo experiments on diabetic mice showed SA/CPBA-MSN/INS sustained a normal blood glucose level for up to 12 h with a single dose. Moreover, the lipid metabolism disorder and organ damage of diabetic mice were alleviated after treatment with SA/CPBA-MSN/INS. Therefore, SA/CPBA-MSN/INS characterized by an "on-off" regulated drug release property and high biosafety shows promise for applications in diabetes treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Hydrogels: synthesis, properties, applications · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou 450001, China

Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou 450001, Henan Province, China

Key Laboratory of Targeting and Diagnosis for Critical Diseases, Zhengzhou 450001, Henan Province, China

Division of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States

Funding

Zhengzhou University · National Natural Science Foundation of China · Henan province

References (44)

Show source-provided references
1. 10.1007/s00109-016-1485-110.1007/s00109-016-1485-1 ↗
2. 10.1016/j.carres.2017.04.00610.1016/j.carres.2017.04.006 ↗
3. 10.1172/JCI3166910.1172/JCI31669 ↗
4. Okada E. · Adv. Peritoneal Dial. · 2015 · 31 · 34
5. 10.1016/j.bbrc.2003.11.01310.1016/j.bbrc.2003.11.013 ↗
6. 10.1161/01.ATV.0000239488.05069.0310.1161/01.ATV.0000239488.05069.03 ↗
7. 10.1021/ja211728x10.1021/ja211728x ↗
8. 10.1039/C5PY00207A10.1039/C5PY00207A ↗
9. 10.1080/09205063.2016.114050310.1080/09205063.2016.1140503 ↗
10. 10.1039/c3cs60436e10.1039/c3cs60436e ↗
11. 10.1002/med.2003810.1002/med.20038 ↗
12. 10.1039/C2SM26690C10.1039/C2SM26690C ↗
13. 10.1002/anie.20110625210.1002/anie.201106252 ↗
14. 10.1021/bm034139o10.1021/bm034139o ↗
15. 10.1039/C4TB00676C10.1039/C4TB00676C ↗
16. 10.1039/C4RA16656F10.1039/C4RA16656F ↗
17. 10.1002/adma.20110476310.1002/adma.201104763 ↗
18. 10.1039/b701744h10.1039/b701744h ↗
19. 10.1002/cite.20170002110.1002/cite.201700021 ↗
20. 10.1039/c2cs15308d10.1039/c2cs15308d ↗
21. 10.1002/anie.20130095810.1002/anie.201300958 ↗
22. 10.1016/j.ajps.2014.05.00410.1016/j.ajps.2014.05.004 ↗
23. 10.1016/j.carbpol.2016.12.04810.1016/j.carbpol.2016.12.048 ↗
24. 10.1016/S0168-3659(02)00214-610.1016/S0168-3659(02)00214-6 ↗
25. 10.1021/nn204240b10.1021/nn204240b ↗
26. 10.1016/j.jconrel.2011.02.01110.1016/j.jconrel.2011.02.011 ↗
27. 10.1039/C4CC04760E10.1039/C4CC04760E ↗
28. 10.1016/j.micromeso.2009.01.00610.1016/j.micromeso.2009.01.006 ↗
29. 10.1074/jbc.M40817920010.1074/jbc.M408179200 ↗
30. 10.1039/C4RA08593K10.1039/C4RA08593K ↗
31. 10.1021/acsami.6b0212110.1021/acsami.6b02121 ↗
32. 10.1021/bm801000610.1021/bm8010006 ↗
33. 10.3967/0895-3988.2012.01.00110.3967/0895-3988.2012.01.001 ↗
34. 10.1002/adma.20160661710.1002/adma.201606617 ↗
35. 10.1056/NEJMoa090835910.1056/NEJMoa0908359 ↗
36. 10.1016/j.jpeds.2012.06.00610.1016/j.jpeds.2012.06.006 ↗
37. 10.2337/dc08-164110.2337/dc08-1641 ↗
38. 10.2217/clp.12.6810.2217/clp.12.68 ↗
39. 10.1021/ja901831u10.1021/ja901831u ↗
40. 10.1039/c1cc12740c10.1039/c1cc12740c ↗
41. Zhang, J. Clinical Endocrine Physiology; China Medical Science Press: Beijing, 1990; pp 291–300.
42. 10.1016/j.ijpharm.2009.11.01210.1016/j.ijpharm.2009.11.012 ↗
43. 10.5958/2277-940X.2016.00008.510.5958/2277-940X.2016.00008.5 ↗
44. 10.1002/0471141755.ph0547s4010.1002/0471141755.ph0547s40 ↗